How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment
Yi Lin, MD, PhD, provides insights on the impact of CAR T-cell therapy on the evolving multiple myeloma treatment landscape.
Video content above is prompted by the following questions:
- What is the impact of CAR T-cell therapy on patient quality of life and how does it compare to other available treatments?
- How do patients typically respond to CAR T-cell therapy in terms of their overall well-being and ability to perform daily activities?
- Are there any long-term quality of life benefits or challenges associated with CAR T-cell therapy?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
